News for Xenon Pharmaceuticals Inc. (XENE)

On June 25, 2025, COMMODORE CAPITAL LP (Trades, Portfolio) made a significant move by acquiring 1,175,000 shares of Cidara Therapeutics Inc (CDTX). This transac

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. RBC Capital maintained its Outperform rating on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and increased its price target from $55 to $57 on June 13. The change comes after the company examined the translatability of previous Phase […]

VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025.

Summary Xenon Pharmaceuticals Inc (XENE), a biopharmaceutical company focused on neuroscience, announced on June 26, 2025, the issuance of equity inducement gra

On May 31, 2025, Driehaus Capital Management LLC made a significant move by acquiring an additional 1,537,303 shares of Septerna Inc at a price of $9.25 per sha

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Summary Xenon Pharmaceuticals Inc (XENE), a leading neuroscience-focused biopharmaceutical company, announced on June 3, 2025, that it will be presenting at the

Summary Xenon Pharmaceuticals Inc (XENE), a biopharmaceutical company focused on neuroscience, announced on May 30, 2025, the issuance of equity inducement gran

**media[641753]**

Trump unveils vision for $175B ‘Golden Dome’ missile defense. Ford to let Nissan use its EV battery plant in Kentucky - report. Wolfspeed craters following potential bankruptcy: report.

On May 14, 2025, Evercore ISI Group announced the initiation of coverage on Xenon Pharmaceuticals (XENE) with an "Outperform" rating. This marks a significant d

We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]

On May 13, 2025, renowned analyst Mohit Bansal from Wells Fargo provided an update on Xenon Pharmaceuticals (XENE). The pharmaceutical company's stock rating re

On May 13, 2025, RBC Capital maintained its "Outperform" rating for Xenon Pharmaceuticals (XENE), while lowering its price target. The updated price target for

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while th...

Revenue: $7.5 million recognized during the first quarter from a milestone payment related to a collaboration with Neurorene.Cash and Cash Equivalents: $691.1

May 12, 2025 / 08:30PM GMTOperator Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welc

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2025 Earnings Conference Call May 12, 2025 4:30 AM ETCorporate ParticipantsChad Fugere - Vice President,...

”“ Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 ”“ Phase